A Worldwide Focus On Carotid Disease and Treatment Options

Wednesday’s Worldwide Podium presentations are part of the Associate Faculty Program at VEITHsymposium, dedicated to featuring research by up-and-coming and lesser known researchers from around the world, excluding Latin America and Asia. Several exciting papers on treating carotid disease will be featured in the morning program.

Symptomatic carotid artery disease risks a futher debilitating event, and in order to best manage the patient, local and international guidelines recommend that a procedure be done within 2 weeks of an initial event in order to gain maximal benefit, according to Dr. Kalpa Perera of Eastern Health in Melbourne, Australia, and colleagues.

Dr. Perera will present the results of a single-center retrospective audit of all cases of symptomatic carotid artery disease that underwent carotid endarterectomy (CEA) over a 1-year period, examining the timing data to treatment.

Of 40 patients included, 30 (75%) had their procedure completed    within the recommended 2-week    timeframe. All cases done within the guidelines were inpatients. In direct contrast, Dr. Perera and his colleagues found that 8 of the 10 patients operated on after 2 weeks were outpatient referrals.
This, according to Dr. Perera “suggests that there may be some unnecessary delays in outpatient referrals and there is scope for improvement.”

Dr. Ignazio Leal, of Complejo Hospitalario De Toledo, Spain, will present a prospective study that evaluated the outcomes of performing a staged transcervical carotid artery stenting (CAS) prior to the use of a flow-reversal method of coronary artery bypass grafting (CABG). The study examined the incidence of myocardial infarction (MI), perioperative stroke, and death at 30 days after intervention.

All of the patients in the study had concomitant severe carotid disease at high risk for endarterectomy as well as coronary disease needing CABG.
Dr. Leal and his colleagues found that there were no deaths, strokes or MI between CAS and CABG, and no strokes at 30-day follow-up after open heart surgery.

None of the patients required cardiac or carotid reinterventions, and there were no cases of postoperative bleeding requiring reoperation.
Dr. Leal will discuss how their results show that staged transcervical CAS with flow-reversal CABG may be a viable alternative for the management of patients with concomitant severe carotid and coronary disease.

Dr. Zhidong Ye, of the China-Japan Friendship Hospital, Beijing, will present a study focusing on the growing practice of performing simultaneous carotid endarterectomy  (CEA) with CABG, vs. isolated CABG. Dr. Ye and colleagues compared results of 12 patients undergoing simultaneous CEA and CABG, compared with 104 patients undergoing only CABG.

Dr. Ye will detail how the addition of CEA to CABG did not increase perioperative morbidity and mortality among the patients, compared to performing an isolated CABG. In addition, no significant differences in intubation time, ICU stay, hospital stay, or local and systemic complications were observed between the two groups.

Wednesday

Worldwide Podium Presentations Session I

8:00 a.m. - 9:55 a.m.

Wednesday’s Worldwide Podium presentations are part of the Associate Faculty Program at VEITHsymposium, dedicated to featuring research by up-and-coming and lesser known researchers from around the world, excluding Latin America and Asia. Several exciting papers on treating carotid disease will be featured in the morning program.

Symptomatic carotid artery disease risks a futher debilitating event, and in order to best manage the patient, local and international guidelines recommend that a procedure be done within 2 weeks of an initial event in order to gain maximal benefit, according to Dr. Kalpa Perera of Eastern Health in Melbourne, Australia, and colleagues.

Dr. Perera will present the results of a single-center retrospective audit of all cases of symptomatic carotid artery disease that underwent carotid endarterectomy (CEA) over a 1-year period, examining the timing data to treatment.

Of 40 patients included, 30 (75%) had their procedure completed    within the recommended 2-week    timeframe. All cases done within the guidelines were inpatients. In direct contrast, Dr. Perera and his colleagues found that 8 of the 10 patients operated on after 2 weeks were outpatient referrals.
This, according to Dr. Perera “suggests that there may be some unnecessary delays in outpatient referrals and there is scope for improvement.”

Dr. Ignazio Leal, of Complejo Hospitalario De Toledo, Spain, will present a prospective study that evaluated the outcomes of performing a staged transcervical carotid artery stenting (CAS) prior to the use of a flow-reversal method of coronary artery bypass grafting (CABG). The study examined the incidence of myocardial infarction (MI), perioperative stroke, and death at 30 days after intervention.

All of the patients in the study had concomitant severe carotid disease at high risk for endarterectomy as well as coronary disease needing CABG.
Dr. Leal and his colleagues found that there were no deaths, strokes or MI between CAS and CABG, and no strokes at 30-day follow-up after open heart surgery.

None of the patients required cardiac or carotid reinterventions, and there were no cases of postoperative bleeding requiring reoperation.
Dr. Leal will discuss how their results show that staged transcervical CAS with flow-reversal CABG may be a viable alternative for the management of patients with concomitant severe carotid and coronary disease.

Dr. Zhidong Ye, of the China-Japan Friendship Hospital, Beijing, will present a study focusing on the growing practice of performing simultaneous carotid endarterectomy  (CEA) with CABG, vs. isolated CABG. Dr. Ye and colleagues compared results of 12 patients undergoing simultaneous CEA and CABG, compared with 104 patients undergoing only CABG.

Dr. Ye will detail how the addition of CEA to CABG did not increase perioperative morbidity and mortality among the patients, compared to performing an isolated CABG. In addition, no significant differences in intubation time, ICU stay, hospital stay, or local and systemic complications were observed between the two groups.

Wednesday

Worldwide Podium Presentations Session I

8:00 a.m. - 9:55 a.m.

Wednesday’s Worldwide Podium presentations are part of the Associate Faculty Program at VEITHsymposium, dedicated to featuring research by up-and-coming and lesser known researchers from around the world, excluding Latin America and Asia. Several exciting papers on treating carotid disease will be featured in the morning program.

Symptomatic carotid artery disease risks a futher debilitating event, and in order to best manage the patient, local and international guidelines recommend that a procedure be done within 2 weeks of an initial event in order to gain maximal benefit, according to Dr. Kalpa Perera of Eastern Health in Melbourne, Australia, and colleagues.

Dr. Perera will present the results of a single-center retrospective audit of all cases of symptomatic carotid artery disease that underwent carotid endarterectomy (CEA) over a 1-year period, examining the timing data to treatment.

Of 40 patients included, 30 (75%) had their procedure completed    within the recommended 2-week    timeframe. All cases done within the guidelines were inpatients. In direct contrast, Dr. Perera and his colleagues found that 8 of the 10 patients operated on after 2 weeks were outpatient referrals.
This, according to Dr. Perera “suggests that there may be some unnecessary delays in outpatient referrals and there is scope for improvement.”

Dr. Ignazio Leal, of Complejo Hospitalario De Toledo, Spain, will present a prospective study that evaluated the outcomes of performing a staged transcervical carotid artery stenting (CAS) prior to the use of a flow-reversal method of coronary artery bypass grafting (CABG). The study examined the incidence of myocardial infarction (MI), perioperative stroke, and death at 30 days after intervention.

All of the patients in the study had concomitant severe carotid disease at high risk for endarterectomy as well as coronary disease needing CABG.
Dr. Leal and his colleagues found that there were no deaths, strokes or MI between CAS and CABG, and no strokes at 30-day follow-up after open heart surgery.

None of the patients required cardiac or carotid reinterventions, and there were no cases of postoperative bleeding requiring reoperation.
Dr. Leal will discuss how their results show that staged transcervical CAS with flow-reversal CABG may be a viable alternative for the management of patients with concomitant severe carotid and coronary disease.

Dr. Zhidong Ye, of the China-Japan Friendship Hospital, Beijing, will present a study focusing on the growing practice of performing simultaneous carotid endarterectomy  (CEA) with CABG, vs. isolated CABG. Dr. Ye and colleagues compared results of 12 patients undergoing simultaneous CEA and CABG, compared with 104 patients undergoing only CABG.

Dr. Ye will detail how the addition of CEA to CABG did not increase perioperative morbidity and mortality among the patients, compared to performing an isolated CABG. In addition, no significant differences in intubation time, ICU stay, hospital stay, or local and systemic complications were observed between the two groups.

Wednesday

Worldwide Podium Presentations Session I

8:00 a.m. - 9:55 a.m.